Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
April 25, 2022 at 07:21 am
Share
Henan Lingrui Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 2,690.03 million compared to CNY 2,328.14 million a year ago. Revenue was CNY 2,693.51 million compared to CNY 2,331.58 million a year ago. Net income was CNY 361.54 million compared to CNY 325.49 million a year ago. Basic earnings per share from continuing operations was CNY 0.65 compared to CNY 0.573 a year ago. Diluted earnings per share from continuing operations was CNY 0.638 compared to CNY 0.573 a year ago.
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
HENAN LINGRUI PHARMACEUTICAL CO., LTD. 